Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories non-GAAP Adjusted Net Earnings ($M) ($M)
Form 8-K Quarterly Earnings Releases (Non-GAAP Reconciliation Tables)
Latest, Q3 2026
2,477
Period ended Sep 30, 2026
Change on a year earlier
+8.7%
2,278 in Q3 2025
History
23 quarters
Since Q1 2021
Sources
19
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up non-gaap adjusted net earnings ($m)
- GAAP Net Earnings — Reconciliation Table ($M)920 · Q3 2026
- Specified Items After-Tax Net Impact ($M)1,557 · Q3 2026
- Non-GAAP Adjusted Earnings Before Taxes ($M)2,920 · Q3 2026
- Non-GAAP Adjusted Gross Margin ($M)7,448 · Q3 2026
- Non-GAAP Adjusted Research & Development Expense ($M)892 · Q3 2026
- Non-GAAP Adjusted Selling, General & Administrative Expense ($M)3,505 · Q3 2026
- Intangible Assets Amortization Expense ($M)841 · Q3 2026
Cite this data
StockData. (2026). Abbott Laboratories Non-GAAP Adjusted Net Earnings ($M) ($M), quarterly Q1 2021–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/ng-net-inc
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.